Anixa Biosciences, Inc. (ANIX)

Anixa Biosciences Income Statement

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 31, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Revenue	-	-	0.21	-	0.51	-
Gross Profit	-	-	0.21	-	0.51	-
Selling, General & Admin	6.58	7.44	6.29	7.17	7.07	5.6
Research & Development	5.41	6.4	4.77	6.7	6.19	4.38
Other Operating Expenses	-	-	0.16	-	0.39	-
Total Operating Expenses	11.99	13.83	11.22	13.88	13.65	9.98
Operating Income	-11.99	-13.83	-11.01	-13.88	-13.14	-9.98
Interest Income	0.77	1.13	1.08	0.1	0	0.03
Other Non-Operating Income (Expense)	-	-	-	-	0.01	-0.15
Total Non-Operating Income (Expense)	0.77	1.13	1.08	0.1	0.01	-0.11
Pretax Income	-11.22	-12.7	-9.93	-13.77	-13.13	-10.09
Net Income	-11.12	-12.55	-9.81	-13.6	-12.95	-10.02
Minority Interest in Earnings	-0.1	-0.14	-0.12	-0.18	-0.17	-0.07
Net Income to Common	-11.12	-12.55	-9.81	-13.6	-12.95	-10.02
Shares Outstanding (Basic)	32	32	31	30	29	22
Shares Outstanding (Diluted)	32	32	31	30	29	22
Shares Change (YoY)	2.01%	2.96%	1.99%	6.28%	28.57%	12.33%
EPS (Basic)	-0.35	-0.39	-0.32	-0.45	-0.45	-0.45
EPS (Diluted)	-0.35	-0.39	-0.32	-0.45	-0.45	-0.45
Free Cash Flow	-6.85	-7.34	-6.21	-6.49	-4.94	-6.19
Free Cash Flow Per Share	-0.21	-0.23	-0.20	-0.21	-0.17	-0.28
Gross Margin	-	-	100.00%	-	100.00%	-
Operating Margin	-	-	-5243.33%	-	-2565.63%	-
Profit Margin	-	-	-4728.57%	-	-2564.06%	-
FCF Margin	-	-	-2956.67%	-	-964.45%	-
EBITDA	-11.95	-13.79	-10.97	-13.83	-13.08	-9.89
EBITDA Margin	-	-	-5221.43%	-	-2553.91%	-
EBIT	-11.99	-13.83	-11.01	-13.88	-13.14	-9.98
EBIT Margin	-	-	-5243.33%	-	-2565.63%	-

Updated Sep 10, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q